Company Technologies Markets Collaborations Investors Careers Contact Search Health Synthetic biology is transforming the development of human and animal therapeutics. The unreliable, costly discovery and development process for new medicines is being replaced by the engineering of biology at the genetic, molecular, and cellular level. Intrexon's ability to regulate complex gene programs and cellular systems at commercial scale is at the forefront of this revolution by applying the principles of science, engineering, and computational bioinformatics with proprietary technologies to design new therapies for humans and animals. Through our Better DNA® approach, Intrexon is currently enabling collaborators to develop targeted gene therapy applications and novel solutions within oncology, rare skin disorders, active pharmaceutical ingredients, ocular diseases, human infertility, infectious diseases, and animal health. Applications & Collaborations Active Pharmaceutical Ingredients Allergic Diseases Cartilage Repair Gastrointestinal & Oral Diseases Human Infertility Infectious Diseases Microbiome Ocular Diseases Oncology Rare Diseases Rare Skin Disorders Pipeline Health Pipeline Opportunities Available opportunities span multiple areas Company Synthetic Biology Our Platform Operating Units & Divisions Subsidiaries Management Board of Directors Our Commitment Technologies UltraVector® RheoSwitch® Cell Systems Informatics Protein Engineering AttSite® Recombinases LEAP® Antibody Discovery Neurospora & Agaricus Platforms Endometrial Regenerative Cells BeyondBio™ Scientific Literature Markets Health Food Energy Environment Consumer Collaborations Exclusive Channel Collaborations Joint Ventures Intrexon Institute for Biomolecular Research Partnering Opportunities Investors Press Releases Stock Information Corporate Governance SEC Filings Events/Conferences Investors Packet FAQ Information Request IRS Form 8937 Careers Contact Legal Notices © 2015 Intrexon